[go: up one dir, main page]

MX2018001720A - Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos. - Google Patents

Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.

Info

Publication number
MX2018001720A
MX2018001720A MX2018001720A MX2018001720A MX2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A
Authority
MX
Mexico
Prior art keywords
sedation
critical care
methods
treatment
use during
Prior art date
Application number
MX2018001720A
Other languages
English (en)
Other versions
MX394213B (es
Inventor
During Matthew
Kazanchyan Anna
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Priority claimed from PCT/US2016/045094 external-priority patent/WO2017027249A1/en
Publication of MX2018001720A publication Critical patent/MX2018001720A/es
Publication of MX394213B publication Critical patent/MX394213B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proveen métodos de sedación a un paciente sometido a tratamiento de cuidado crítico utilizando gaboxadol intravenoso o una sal farmacéuticamente aceptable del mismo. Se proveen formulaciones parenterales para sedación en cuidado crítico utilizando gaboxadol o una sal farmacéuticamente aceptable del mismo. Las formulaciones parenterales son particularmente bien adecuadas para usarse en sedación para cuidado crítico.
MX2018001720A 2015-08-11 2016-08-02 Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. MX394213B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203731P 2015-08-11 2015-08-11
US201562203748P 2015-08-11 2015-08-11
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment
PCT/US2016/045094 WO2017027249A1 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Publications (2)

Publication Number Publication Date
MX2018001720A true MX2018001720A (es) 2018-09-06
MX394213B MX394213B (es) 2025-03-24

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001720A MX394213B (es) 2015-08-11 2016-08-02 Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.

Country Status (12)

Country Link
US (1) US20180235942A1 (es)
EP (1) EP3334427A4 (es)
JP (1) JP6857647B2 (es)
KR (1) KR20180048707A (es)
CN (1) CN108135889A (es)
AU (1) AU2016304737B2 (es)
CA (1) CA2994952A1 (es)
CO (1) CO2018002534A2 (es)
IL (1) IL257296B2 (es)
MX (1) MX394213B (es)
PE (1) PE20181332A1 (es)
TW (1) TWI763632B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014393A1 (en) 2015-07-17 2017-01-19 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CN112930182A (zh) 2018-09-20 2021-06-08 奥维德医疗公司 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US20220218740A1 (en) * 2020-10-25 2022-07-14 Vaporworks Nursing Anesthesia Inc. Opioid-free compositions for anesthesiological applications and related methods and systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1742624B1 (en) * 2004-02-18 2010-01-06 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
AU2016304737B2 (en) 2021-03-11
TW201717944A (zh) 2017-06-01
IL257296B2 (en) 2023-02-01
EP3334427A4 (en) 2019-02-06
EP3334427A1 (en) 2018-06-20
JP6857647B2 (ja) 2021-04-14
MX394213B (es) 2025-03-24
CA2994952A1 (en) 2017-02-16
CO2018002534A2 (es) 2018-05-31
CN108135889A (zh) 2018-06-08
JP2018522920A (ja) 2018-08-16
KR20180048707A (ko) 2018-05-10
AU2016304737A1 (en) 2018-02-22
IL257296A (en) 2018-03-29
TWI763632B (zh) 2022-05-11
US20180235942A1 (en) 2018-08-23
IL257296B (en) 2022-10-01
PE20181332A1 (es) 2018-08-20

Similar Documents

Publication Publication Date Title
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CR20140086A (es) Tratamientos de combinación para hepatitis c
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
MX2019014024A (es) Tratamiento de los trastornos depresivos.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
HUE054137T2 (hu) NX-1207 jóindulatú prosztatamegnagyobbodásban szenvedõ páciensek kezelésében sebészeti beavatkozás szükségességének csökkentésére történõ alkalmazásra
HUE058151T2 (hu) Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EP3203995A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS